Table 4.
Selected clinical parameters in patients during treatment
| Group | Time | PO2 (mmHg) | CK-MB (U/L) | ALT (U/L) | Cr (umol/L) |
|---|---|---|---|---|---|
| HP | 0 | 93.20±11.82 | 14.30±9.21 | 45.17±12.33 | 88.92±21.30 |
| 3 days | 69.31±6.32 | 32.81±12.77 | 165.77±22.99 | 195.33±26.88 | |
| 7 days | 54.92±8.22 | 38.14±11.27 | 402.65±20.40 | 315.49±30.71 | |
| HP + Xuebijing | 0 | 92.50±9.11 | 13.81±10.94 | 47.20±11.95 | 89.62±20.58 |
| 3 days | 90.12±10.35 | 17.27±8.52 | 68.51±22.34 | 99.80±26.38 | |
| 7 days | 77.50±14.67 | 23.52±16.89 | 102.55±24.21 | 100.21±5.64 | |
| HP + ulinastatin | 0 | 91.27±8.16 | 14.22±8.59 | 44.92±11.52 | 86.38±25.34 |
| 3 days | 88.85±10.87 | 22.74±8.35 | 99.81±14.54 | 132.27±22.11 | |
| 7 days | 74.51±9.66 | 33.26±11.23 | 212.44±12.28 | 216.54±15.89 |